[ad_1]
Valneva logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File photo Acquire Licensing Rights
Nov 27 (Reuters) – French drugmaker Valneva (VLS.PA) said on Monday that the application for its vaccine candidate against mosquito-borne viral disease chikungunya was accepted by the European Medicines Agency (EMA) which would now examine the drug in a fast-track procedure.
The EMA “has determined that all essential regulatory elements required for scientific assessment were included in the application,” Valneva said in a statement.
Accelerated assessment reduces the timeframe the EMA review to 150 days from 210 days, Valneva said.
Reporting by Olivier Sorgho
Our Standards: The Thomson Reuters Trust Principles.
|
Sources 2/ https://www.reuters.com/business/healthcare-pharmaceuticals/valneva-says-eu-regulator-accepts-its-chikungunya-vaccine-application-2023-11-27/ The mention sources can contact us to remove/changing this article |
[ad_2]